Banner-ASU Neuroscience Scholars is a paid, eight-week training program open to top-achieving college undergraduate and graduate science and social science students. Scholars work full-time on a research project under the mentorship of a Banner Research or ASU-Biodesign scientist or clinician to unlock medical and scientific mysteries in the areas of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, in a lab or clinical setting in the Greater Phoenix metropolitan area.Continue reading
Author Archive: AZBio
Temporary Restraining Order Granted for 22 States on NIH 15 Percent Cap on Indirect Costs
U.S. District Judge Angel Kelly granted a temporary restraining order on Feb. 10, 2025 related to changes announced on Feb. 7, related to how the National Institutes of Health reimburses Facilities and Administrative (F&A) costs also known as indirect costs. Judge Kelley set an in-person hearing for Feb. 21, 2025.Continue reading
HonorHealth Research Institute’s Chief Medical Officer is recognized by the world’s leading organization for cancer doctors
Dr. Michael S. Gordon is named as a Fellow of the American Society of Clinical OncologyContinue reading
NIH Announces New Indirect Cost Rates of 15%
NIH announced on February 7, 2025 that effective Monday, February 10, 2025, “In accordance with 45 CFR 75 and its accompanying appendices, this Guidance implements and makes publicly available NIH’s updated policy deviating from the negotiated indirect cost rate for new grant awards and existing grant awards, effective as of the date of this Guidance’s issuance. Pursuant to this Supplemental Guidance, there will be a standard indirect rate of 15% across all NIH grants for indirect costs in lieu of a separately negotiated rate for indirect costs in every grant.”
Read Notice Number NOT-OD-25-068 for more information.Continue reading
AZBio CEO Shares Insights on Health Innovation in Arizona with the House Science and Technology Committee
Joan Koerber-Walker, President & CEO of the Arizona Bioindustry Association (AZBio), shares a look at the past, present, and future of health innovation in Arizona in this presentation to the Arizona House of Representatives Science and Technology Committee on 2/5/2025.Continue reading
Finance Committee Members Introduce Bipartisan Legislation to Ensure Medicare Patients’ Access to Cancer Detection Technologies
Washington, D.C.–U.S. Senate Finance Committee Chairman Mike Crapo (R-Idaho) and Finance Committee member Michael Bennet (D-Colorado), with Ranking Member Ron Wyden (D-Oregon) and Finance Committee member Tim Scott (R-South Carolina), reintroduced the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act that would ensure Medicare beneficiaries’ access to cutting-edge tests capable of detecting multiple types of cancer before symptoms appear. Bipartisan companion legislation (H.R. 842) was also introduced in the U.S. House of Representatives. Continue reading
TGen researchers create spatial map of gene expression in pulmonary fibrosis
Unique look revealed signs of disease prior to lung remodelingContinue reading
XLR8 PBC Applications Open for Scale-Ready Health Tech Companies; Esteemed Mentor Lineup Announced
Phoenix, AZ – XLR8 PBC, Arizona’s premier program for scale-ready health tech companies, is now accepting applications for its latest cohort. With a no-cost, no-equity structure, XLR8 PBC provides health tech companies with unparalleled access to industry leaders, mentorship, and strategic resources. Applications for the program are open until February 19, 2025, offering founders the opportunity to engage with a world-class team of mentors and position their ventures for accelerated growth.Continue reading
Flinn-Brown application opens. Apply by Feb. 28
The Flinn-Brown Fellowship is a statewide civic leadership program like no other.Continue reading
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years —
— JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain —Continue reading